Sagimet Biosciences Soars 10.6% on Upgraded Price Target

On June 16, 2025, Sagimet Biosciences saw a significant rise of 10.6% in pre-market trading, indicating strong investor interest and potential market momentum.

Jones Trading recently upgraded their price target for Sagimet Biosciences, increasing it from $15.00 to $27.00 and maintaining a "buy" rating. This move reflects growing confidence in the company's prospects and its potential for future growth.

Sagimet Biosciences is set to host a virtual Key Opinion Leader (KOL) event titled "A New Mechanism of Action in Treating Acne: Update on Positive Phase 3 Denifanstat Trial for the Treatment of." This event is expected to provide valuable insights into the company's latest developments and clinical trial results, which could further influence investor sentiment.